Your browser doesn't support javascript.
loading
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Prat, Aleix; Pascual, Tomás; De Angelis, Carmine; Gutierrez, Carolina; Llombart-Cussac, Antonio; Wang, Tao; Cortés, Javier; Rexer, Brent; Paré, Laia; Forero, Andres; Wolff, Antonio C; Morales, Serafín; Adamo, Barbara; Brasó-Maristany, Fara; Vidal, Maria; Veeraraghavan, Jamunarani; Krop, Ian; Galván, Patricia; Pavlick, Anne C; Bermejo, Begoña; Izquierdo, Miguel; Rodrik-Outmezguine, Vanessa; Reis-Filho, Jorge S; Hilsenbeck, Susan G; Oliveira, Mafalda; Dieci, Maria Vittoria; Griguolo, Gaia; Fasani, Roberta; Nuciforo, Paolo; Parker, Joel S; Conte, PierFranco; Schiff, Rachel; Guarneri, Valentina; Osborne, C Kent; Rimawi, Mothaffar F.
Afiliação
  • Prat A; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.
  • Pascual T; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • De Angelis C; Scientific Department, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.
  • Gutierrez C; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.
  • Llombart-Cussac A; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Wang T; Scientific Department, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.
  • Cortés J; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
  • Rexer B; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.
  • Paré L; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
  • Forero A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.
  • Wolff AC; Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain.
  • Morales S; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
  • Adamo B; IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain.
  • Brasó-Maristany F; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Vidal M; Department of Medicine, Vanderbilt University, Nashville, TN.
  • Veeraraghavan J; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.
  • Krop I; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Galván P; Scientific Department, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.
  • Pavlick AC; Department of Medicine, University of Alabama-Birmingham, Birmingham, AL.
  • Bermejo B; Johns Hopkins University, Baltimore, MD.
  • Izquierdo M; Department of Medical Oncology, Hospital Universitari Arnau Vilanova, Lleida, Spain.
  • Rodrik-Outmezguine V; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.
  • Reis-Filho JS; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Hilsenbeck SG; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.
  • Oliveira M; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Dieci MV; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.
  • Griguolo G; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Fasani R; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
  • Nuciforo P; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.
  • Parker JS; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
  • Conte P; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.
  • Schiff R; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Guarneri V; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
  • Osborne CK; Department of Medical Oncology, Hospital Clínico de Valencia, Valencia, Spain.
  • Rimawi MF; Novartis Oncology, Basel, Switzerland.
J Natl Cancer Inst ; 112(1): 46-54, 2020 01 01.
Article em En | MEDLINE | ID: mdl-31037288
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Expressão Gênica / Receptor ErbB-2 / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Expressão Gênica / Receptor ErbB-2 / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos